Cochrane · systematic review · CD001904
Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review
Nevitt, SJ, Marson, AG, Tudur Smith, C · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
9
current version
GRADE rated
9
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 6 · 66.7%Moderate 3 · 33.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 3 versionsCarbamazepine compared with phenobarbitone for epilepsy (time to treatment failure)
Population: adults and children with newly onset focal or generalised epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Time to treatment failure (any reason related to treatment) All participants Range of Carbamazepine vs phenobarbitone | HR 0.66 [0.5, 0.86] | 4 studies · 676 participants | Moderate Downgraded: risk of bias, inconsistency |
Time to treatment failure (any reason related to treatment) Subgroup: focal onset seizures Range of Carbamazepine vs phenobarbitone | HR 0.66 [0.49, 0.88] | 4 studies · 520 participants | Low Downgraded: risk of bias, inconsistency |
Time to treatment failure (any reason related to treatment) Subgroup: generalised onset tonic‐clonic seizures Range of Carbamazepine vs phenobarbitone | HR 0.65 [0.35, 1.23] | 3 studies · 156 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Carbamazepine compared with phenobarbitone for epilepsy (secondary outcomes)
Population: adults and children with newly onset focal or generalised epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Time to first seizure (post‐randomisation) All participants Range of Carbamazepine vs phenobarbitone | HR 1.13 [0.93, 1.38] | 6 studies · 822 participants | Moderate Downgraded: risk of bias, inconsistency |
Time to first seizure (post‐randomisation) Subgroup: focal onset seizures Range of Carbamazepine vs phenobarbitone | HR 1.31 [1.04, 1.66] | 6 studies · 584 participants | Moderate Downgraded: risk of bias, inconsistency |
Time to first seizure (post‐randomisation) Subgroup: generalised onset tonic‐clonic seizures Range of Carbamazepine vs phenobarbitone | HR 0.8 [0.55, 1.15] | 5 studies · 238 participants | Low Downgraded: risk of bias, inconsistency |
Time to achieve 12‐month remission (seizure‐free period) All participants Range of Carbamazepine vs phenobarbitone | HR 1.09 [0.84, 1.4] | 4 studies · 683 participants | Low Downgraded: risk of bias, inconsistency |
Time to achieve 12‐month remission (seizure‐free period) Subgroup: focal onset seizures Range of Carbamazepine vs phenobarbitone | HR 0.92 [0.67, 1.25] | 4 studies · 525 participants | Low Downgraded: risk of bias, inconsistency |
Time to achieve 12‐month remission (seizure‐free period) Subgroup: generalised onset tonic‐clonic seizures Range of Carbamazepine vs phenobarbitone | HR 1.56 [0.99, 2.44] | 3 studies · 158 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |